Ablynx Archives

News and Trends 23 May 2017

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […]

May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Mar 2017

Merck Outsources the Development of its Nanobody for Psoriasis

Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody […]

March 30, 2017 - 3 minutesmins - By Melanie De Almeida

Best in Biotech 15 Mar 2017

What are the Best Countries to Recruit Biotech Talents in 2017?

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what you can expect from each cluster. For each one of them, we also referenced some data on the biotech, life science and research ecosystems to […]

March 15, 2017 - 10 minutesmins - By External Contributor

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 11 Jan 2017

UPDATE: The 5 Hottest European Biotechs in 2017 according to JP Morgan

The world’s biggest biotech investor conference, hosted by JP Morgan, is now underway in San Francisco, and European companies are putting up a strong showing. Here are those (in chronological order) who made the cut to present at this invite-only event. We’ll update the post as companies present! While uniQure has hit a number of rough […]

January 11, 2017 - 3 minutesmins - By Evelyn Warner

rheumatoid arthritis anti il 6r ablynx abbvie

News and Trends 9 Aug 2016

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

Ablynx has disclosed ‘compelling’ results for its Phase IIb trial in rheumatoid arthritis. But it might have a hard time compelling AbbVie to pay €68M to continue the candidate’s development, as the grass is not as green as it seems… Ablynx‘s impressive list of big Pharma collaborations could soon need an update, as its $840 partnership with […]

August 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

abbvie ablynx rheumatoid arthritis nanobody

News and Trends 11 Jul 2016

Nanobody Phase II Results for Arthritis: Good but not good enough?

Ablynx has shown that its candidate for Rheumatoid arthritis could work as a monotherapy, but whether they can convince AbbVie to stick to the previous $840M deal is still unclear. Ghent-based Ablynx has hooked several big Pharmas with its Nanobody platform, based on the shorter monoclonal antibodies of llamas. One of these is AbbVie (France), which is […]

July 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

ablynx llama antigody nanobody rsv infant

News and Trends 3 May 2016

Llama Antibody Inhalation gets Positive Results for Respiratory Virus

Ablynx has gotten positive results for its candidate (ALX-0171) in Phase I/IIa trial for infants infected with a life-threatening virus – respiratory syncytial virus (RSV). Located near Ghent (Belgium), Ablynx is making advances in its Nanobody platform, based on the shorter monoclonal antibodies of llamas. Due to their small size, these Nanobodies can be used in a […]

May 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 29 Feb 2016

Our Top 5 Articles on Biotech & Rare Disease

Today is Rare Disease Day 2016. Because it is an important field for Biotech, we went back to review some of our best articles on the topic from the Labiotech archives. Here are some of our best – in addition to an overview of 7 Rare diseases and who in Biotech is working on them. Nº […]

February 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

alpaca nejm purpura thrombocytopenia blood titan hercules

News and Trends 16 Feb 2016

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

Ablynx, the llama antibody biotech in Belgium, has now proven to be on solid ground regarding their orphan drug for a rare blood disease. Now the New England Journal of Medicine has published their phase II results. Ablynx often makes our biotech headlines, be it with the curious science of their nanobody platform or with their partnerships with […]

February 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

llama leo pharma argen x skin milestone inflammatory

News and Trends 3 Feb 2016

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody pipeline which Leo Pharma (Denmark), is developing to treat inflammatory skin conditions. These llama mAb platforms allow arGEN-X to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. This is a similar approach to which Ablynx […]

February 3, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease… Ablynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Ablynx

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Merck Outsources the Development of its Nanobody for Psoriasis

What are the Best Countries to Recruit Biotech Talents in 2017?

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

UPDATE: The 5 Hottest European Biotechs in 2017 according to JP Morgan

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

Nanobody Phase II Results for Arthritis: Good but not good enough?

Llama Antibody Inhalation gets Positive Results for Respiratory Virus

Our Top 5 Articles on Biotech & Rare Disease

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!